Insider Ledger
GLUE insider buying and SEC filings, explained
Monte Rosa Therapeutics, Inc. · CIK 1826457
Tracked: Forms 3/4/5, 8-K, NT · All filings on sec.gov
Company profile
- Exchanges
- Nasdaq
- Industry (SIC)
- Biological Products, (No Diagnostic Substances)
- State of incorporation
- DE
- Fiscal year end
- Dec 31
- Former names
- Monte Rosa Therapeutics, Inc.
Insider activity in the last 12 months
Bought
$0
Insiders who bought
0
Sold (not marked 10b5-1)
$1.0M
Planned sales (10b5-1)
$2.2M
Insider purchases and sales, last 12 months
| Traded | Type | What was filed | Source |
|---|---|---|---|
| Oct 5, 2026 | Sale | Matthew Bowen (Principal Accounting Officer) sold 13 shares at $10.56 ($137). Holdings down <1% to 25,891 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Oct 6, 2026, 4:05 PM ET |
| Jul 16, 2026 | Sale | Markus Warmuth (CEO and Director) sold 9,500 shares at about $23.18 ($220K). Holdings down 2% to 585,038 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jul 17, 2026 |
| Jul 15, 2026 | Planned (10b5-1) | Jennifer Champoux (President / COO) sold 4,351 shares at about $23.38 ($102K), marked as a 10b5-1 plan trade. Holdings down 7% to 62,371 shares. | SEC filing Filed Jul 16, 2026 |
| Jul 6, 2026 | Planned (10b5-1) | Sharon Townson (Chief Scientific Officer) sold 6,000 shares at about $23.31 ($140K), marked as a 10b5-1 plan trade. Holdings down 8% to 67,845 shares. | SEC filing Filed Jul 7, 2026 |
| Jun 30, 2026 | Planned (10b5-1) | Filip Janku (Chief Medical Officer) sold 5,407 shares at $24.50 ($132K), marked as a 10b5-1 plan trade. Holdings down 8% to 60,612 shares. | SEC filing Filed Jul 1, 2026 |
| Jun 29, 2026 | Planned (10b5-1) | Filip Janku (Chief Medical Officer) sold 6,000 shares at $22.95 ($138K), marked as a 10b5-1 plan trade. Holdings down 9% to 59,992 shares. | SEC filing Filed Jun 30, 2026 |
| Jun 23–24, 2026 | Planned (10b5-1) | Filip Janku (Chief Medical Officer) sold 41,845 shares between Jun 23 and Jun 24 at about $21.08 ($882K), marked as a 10b5-1 plan trade. Holdings down 41% to 59,992 shares. | SEC filing Filed Jun 25, 2026 |
| Jun 23, 2026 | Planned (10b5-1) | Sharon Townson (Chief Scientific Officer) sold 3,000 shares at $20.00 ($60K), marked as a 10b5-1 plan trade. Holdings down 4% to 67,845 shares. | SEC filing Filed Jun 25, 2026 |
| Jun 23, 2026 | Planned (10b5-1) | Jennifer Champoux (President / COO) sold 2,175 shares at $20.00 ($44K), marked as a 10b5-1 plan trade. Holdings down 3% to 62,371 shares. | SEC filing Filed Jun 25, 2026 |
| Jun 17, 2026 | Planned (10b5-1) | Jennifer Champoux (President / COO) sold 2,176 shares at $19.00 ($41K), marked as a 10b5-1 plan trade. Holdings down 3% to 62,371 shares. | SEC filing Filed Jun 18, 2026 |
| Jun 17, 2026 | Planned (10b5-1) | Sharon Townson (Chief Scientific Officer) sold 3,000 shares at $19.00 ($57K), marked as a 10b5-1 plan trade. Holdings down 4% to 67,845 shares. | SEC filing Filed Jun 18, 2026 |
| Jun 1, 2026 | Planned (10b5-1) | Markus Warmuth (CEO and Director) sold 5,466 shares at about $19.44 ($106K), marked as a 10b5-1 plan trade. Holdings down 1% to 594,538 shares. | SEC filing Filed Jun 2, 2026 |
| May 29, 2026 | Planned (10b5-1) | Sharon Townson (Chief Scientific Officer) sold 6,000 shares at about $19.87 ($119K), marked as a 10b5-1 plan trade. Holdings down 8% to 67,845 shares. | SEC filing Filed Jun 1, 2026 |
| May 27, 2026 | Planned (10b5-1) | Jennifer Champoux (President / COO) sold 2,175 shares at $20.00 ($44K), marked as a 10b5-1 plan trade. Holdings down 3% to 62,371 shares. | SEC filing Filed May 28, 2026 |
| May 22, 2026 | Planned (10b5-1) | Jennifer Champoux (President / COO) sold 2,176 shares at $19.00 ($41K), marked as a 10b5-1 plan trade. Holdings down 3% to 62,371 shares. | SEC filing Filed May 26, 2026 |
| May 1, 2026 | Planned (10b5-1) | Markus Warmuth (CEO and Director) sold 5,467 shares at about $18.92 ($103K), marked as a 10b5-1 plan trade. Holdings down 1% to 600,004 shares. | SEC filing Filed May 5, 2026 |
| Apr 14, 2026 | Sale | Markus Warmuth (CEO and Director) sold 8,000 shares at about $17.64 ($141K). Holdings down 1% to 605,471 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Apr 15, 2026 |
| Apr 9, 2026 | Sale | Philip Nickson (Chief Business & Legal Officer) sold 5,845 shares at about $17.69 ($103K). Holdings down 10% to 55,000 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Apr 10, 2026 |
| Mar 4, 2026 | Sale | Edmund Dunn (Principal Accounting Officer) sold 139 shares at $17.96 ($2K). Holdings down 1% to 22,554 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 5, 2026 |
| Mar 2, 2026 | Planned (10b5-1) | Markus Warmuth (CEO and Director) sold 5,466 shares at about $17.92 ($98K), marked as a 10b5-1 plan trade. Holdings down 1% to 613,471 shares. | SEC filing Filed Mar 4, 2026 |
| Feb 23, 2026 | Sale | Filip Janku (Chief Medical Officer) sold 9,189 shares at $19.50 ($179K). Holdings down 12% to 65,837 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Feb 24, 2026 |
| Jan 7, 2026 | Planned (10b5-1) | Markus Warmuth (CEO and Director) sold 5,466 shares at about $23.48 ($128K), marked as a 10b5-1 plan trade. Holdings down 1% to 618,937 shares. | SEC filing Filed Jan 9, 2026 |
| Jan 5, 2026 | Sale | Edmund Dunn (Principal Accounting Officer) sold 1,039 shares at about $15.17 ($16K). Holdings down 4% to 22,693 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jan 5, 2026 |
| Jan 5, 2026 | Sale | Philip Nickson (Chief Business & Legal Officer) sold 3,155 shares at about $15.17 ($48K). Holdings down 5% to 60,845 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jan 5, 2026 |
| Jan 5, 2026 | Sale | Jennifer Champoux (President / COO) sold 2,629 shares at about $15.17 ($40K). Holdings down 4% to 62,371 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jan 5, 2026 |
| Jan 5, 2026 | Sale | Markus Warmuth (CEO and Director) sold 10,135 shares at about $15.17 ($154K). Holdings down 2% to 624,403 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jan 5, 2026 |
| Jan 5, 2026 | Sale | Filip Janku (Chief Medical Officer) sold 3,155 shares at about $15.17 ($48K). Holdings down 4% to 75,026 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jan 5, 2026 |
| Jan 5, 2026 | Sale | Sharon Townson (Chief Scientific Officer) sold 3,155 shares at about $15.17 ($48K). Holdings down 4% to 67,845 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jan 5, 2026 |
32 routine transactions (such as grants, option exercises or tax withholding) are not listed.
Cluster buys
No cluster buys in the last 12 months.
Red flags
No red flags in the last 12 months.
Key events
No key events in the last 12 months.
8-K filings, last 12 months
No 8-K filings in the last 12 months.
Red flags are objective triggers only: the item or form filed, never an opinion.
Follow GLUE in the Insider Ledger app
Get the appA plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.